Genentech is cutting over 100 jobs at its South San Francisco headquarters while advancing key drug candidates through FDA review. The biotech giant is simultaneously losing senior scientists to competitors even as its KRAS inhibitor divarasib and thyroid eye disease therapy secure regulatory wins.
·More than 100 jobs eliminated at headquarters, including veteran scientists and three vice presidents
·Divarasib shows superiority in phase III trial against other KRAS G12C inhibitors for non-small cell lung cancer
·Enspryng subcutaneous therapy receives FDA priority review for thyroid eye disease with potential at-home dosing
·Key executives departing to competitors including ex-iTeos CEO now at GSK
·Restructuring signals strategic shift despite pipeline advancement
drawn from San Francisco Chronicle, The Business Journals, BioWorld News, Eyes On Eyecare · updated 1h ago